leadf
logo-loader
viewNovavax, Inc.

Novavax expects to submit COVID-19 vaccine before US authorities in December

Data from the second phase of clinical trials is expected in the fourth quarter of 2020

Novavax, Inc. - Novavax expects to submit COVID-19 vaccine before US authorities in December

Novavax Inc (NASDAQ:NVAX) is reportedly expecting to submit its COVID-19 vaccine candidate before US authorities in December.

Chief executive Stanley Erck told Czech paper Hospodarske Noviny that it plans to produce some of the jabs in its Czech plant, so the country will be able to access it if it is approved.

READ: Novavax to provide 60mln COVID-19 vaccine doses to UK government

On Monday the biotech enrolled the first volunteer for the Phase II of clinical trials in late August, expanding on Phase I by including older adults 60-84 years of age.

Data is expected in the fourth quarter of 2020.

Shares added 3% to US$118.30 in premarket trading.

Quick facts: Novavax, Inc.

Price: 124.63 USD

NASDAQ:NVAX
Market: NASDAQ
Market Cap: $7.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Great Bear Resources releases 7 new drill holes from LP fault that show high...

Great Bear Resources (CVE: GBR- OTCQX: GTBAF) CEO Chris Taylor joined Steve Darling from Proactive to share details about 7 new drill holes from the LP Fault. These results part of their 25-million-dollar 2021 exploration program. Taylor telling Proactive they published 227 LP Fault drill...

1 hour, 42 minutes ago

2 min read